Compare KARO & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KARO | AVLN |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2026 |
| Metric | KARO | AVLN |
|---|---|---|
| Price | $62.87 | $37.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $59.33 | N/A |
| AVG Volume (30 Days) | 95.6K | ★ 168.2K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.17 | N/A |
| Revenue Next Year | $16.74 | N/A |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.25 | $24.90 |
| 52 Week High | $67.14 | $40.17 |
| Indicator | KARO | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 64.87 |
| Support Level | $61.63 | $26.38 |
| Resistance Level | $66.67 | $39.99 |
| Average True Range (ATR) | 2.16 | 2.55 |
| MACD | -0.65 | 0.62 |
| Stochastic Oscillator | 39.19 | 81.03 |
Karooooo Ltd is a provider of an operational intelligence platform. Through its cloud platform, the company enables fleet and asset management, fuel management, workforce management, logistics, safety, including AI-assisted video safety, compliance, risk, and environmental impact management. Its segments are: Cartrack, which generates the majority of revenue, provides an operational intelligence platform that maximizes the value of transportation, operations, and workflow data through insightful real-time data analytics to connected vehicles and equipment, and Karooooo Logistics provides a software application enabling the management of last-mile B2B delivery and general operational logistics (Delivery-as-a-Service or DaaS). It generates the majority of its revenue from South Africa.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.